Highly respected key opinion leaders
Synedgen science advisors include internationally respected leaders in multiple disciplines including oral and ophthalmic health; gastrointestinal health and antimicrobial resistance; and mucosal infection, radiation and immunology. This team advises appropriate design of drug administration, critiques drug development plans and trial design, and also assesses the potential impact of the drug for strategic partners and investors.
Richard Tuli, MD, PhD
Dr. Richard Tuli is a radiation oncologist who specializes in the research and treatment of gastrointestinal cancers, including pancreatic, colorectal, esophageal, and stomach cancers, and liver and bile duct tumors. He earned combined MD and PhD degrees from Jefferson Medical College in Philadelphia, followed by residency training at Johns Hopkins Hospital in Baltimore where he also served as Chief Resident.
His current research is directed toward integrating novel molecular and targeted therapies, such as PARP inhibitors and immune therapies, with state-of-the-art radiation technologies for the treatment of pancreatic and other gastrointestinal cancers. He has been principal investigator of many clinical trials in pancreatic cancer, served on numerous national scientific boards and leadership committees pertaining to gastrointestinal cancers, and has authored more than 100 articles, editorials, and book chapters. He continues to teach and mentor students, residents, and fellows, many of whom have gone on to work at prominent research institutions.
Phil Burns
Mr. Burns has more than 25 years experience in the senior Pharmaceutical Operations environment including site organizational design, management, and product introductions, and Quality Compliance /Technical Production experience including cGMP compliance, Quality Assurance and Compliance, and Regulatory Affairs. He has overseen retooling and reformulation of products produced on the billion-pill scale to building manufacturing facilities for liquids, emulsions and powder/capsules.
Mike Gil
Mr. Gil is a skilled Regulatory, QA, QC compliance specialist with an extensive knowledge of quality assurance and quality control systems, document controls and regulatory requirements. He has 27 years of experience in the pharmaceutical industry with extensive knowledge of managing US FDA, EU and German regulatory authority inspections for US manufacturing facilities, and provides a full service of regulatory and compliance consultation for the pharmaceutical industry, including regulatory, cGMP, cGLP, and cGCP compliance.
Jeff Staffa
Jeffrey A. Staffa has had extensive experience in all aspects of the pharmaceutical industry spanning a career of over 30 years. He has worked for the U.S. FDA, a small privately held company, a small publicly held company, a large publicly held company, and the largest chemical company in the world. He has worked and participated in regulatory affairs, x-ray crystallography, medicinal and agricultural chemical synthesis, pilot plant manufacturing, quality control, safety surveillance, preclinical toxicological evaluation, pharmacokinetics, clinical pharmacology, and clinical development. He has served as the scientific advisor to attorneys working for the federal government and for numerous companies. He has advised Commissioners of the FDA and prepared FDA General Counsel for hearings and trials. He is fluent in the business aspects of the pharmaceutical industry. He has worked with biologics, drugs, devices, foods, and veterinary products.
Kim Snyder
Kim has 20 years of experience in financial reporting, budgeting and forecasting, mergers and acquisitions, and divestitures. Her industry experience includes public accounting, manufacturing, pharmaceutical and healthcare in for profit and not for profit organizations. Kim holds a BA in Accounting & Business Management and a MBA with a focus on accounting and finance.